Ask us a question
520 547-3440
info@c-path.org
Subscribe
Donate
Home
About
HOW WE OPERATE
Breadth of Expertise
Core Competencies
Timeline
People
FAQ
Employment
Annual Reports
Programs
Sharing Knowledge that Leads to Innovation
ACTIVE CONSORTIA / PROGRAMS
BmDR
Biomarker Data Repository
CPAD
Critical Path for Alzheimer’s Disease
CPP
Critical Path for Parkinson’s
CP-SCD
Critical Path for Sickle Cell Disease
CPTA
Critical Path to Therapeutics for the Ataxias
CDRC
CURE Drug Repurposing Collaboratory
DCC
Data Collaboration Center
D-RSC
Duchenne Regulatory Science Consortium
eCOA Consortium
Electronic Clinical Outcome Assessment Consortium
FA-ICD
Friedreich’s Ataxia Integrated Clinical Database
HD-RSC
Huntington’s Disease Regulatory Science Consortium
INC
International Neonatal Consortium
MSOAC
Multiple Sclerosis Outcome Assessments Consortium
PRO Consortium
Patient-Reported
Outcome Consortium
PKDOC
Polycystic Kidney Disease Outcomes Consortium
PredicTox KE
PredicTox Knowledge Environment
PSTC
Predictive Safety Testing Consortium
QuantMed
Quantitative Medicine Program
RDCA-DAP
Rare Disease Cures Accelerator-Data and Analytics Platform
RD-COA Consortium
Rare Disease Clinical Outcome Assessment Consortium
TB-PACTS
TB-Platform for Aggregation of Clinical TB Studies
TTC
Transplant Therapeutics Consortium
TOMI-T1D
Trial Outcome Markers Initiative in T1D Consortium
TRxA
Translational Therapeutics Accelerator
T1D
Type 1 Diabetes Consortium
Completed Consortia
CFAST
Coalition for Accelerating Standards & Therapies
CPTR
Critical Path to TB Drug Regimens
PTC
Pediatric Trials Consortium
C-Path in Europe
Tools & Platforms
Impact
Impact Stories
Successes
Evidentiary Considerations
News & Events
Events
News
Videos
Publications
Presentations
Press Releases
Education
News
Home
>
News & Events
>
Pharmaceutical Industry Members
>
Actelion Pharmaceuticals Ltd.
News
May 2, 2013
PRINT
PDF
Actelion Pharmaceuticals Ltd.
Related Posts
Diamyd Medical Joins International Consortium in Type 1 Diabetes
C-Path and Replica Analytics Collaboration Aims to Accelerate Rare Disease Research
C-Path Welcomes RWS
How can natural language processing help model informed drug development?: a review
C-Path Welcomes Parexel
x
